Visara Inc Faces Capital Depletion Risk as VIS-101 Ophthalmology Drug Progresses to Commercialization
Visara Inc, a NovaBridge subsidiary developing VIS-101 for wet AMD and diabetic macular edema, faces medium-likelihood catastrophic risk of capital runway depletion before commercialization. Ophthalmology drug development costs threaten funding adequacy for the biologic therapeutic candidate targeting retinal diseases.
ViaNews Editorial Team (Markets)•